LIF Participated in BioAsia 2014

     LIF participated in BioAsia 2014, The Global Bio Business Forum where Santa Fe’s province had a stand.

     The Forum took place on February 17th, 18th and 19th, in Hyderabad, India,
     Santa Fe’s Governor, Antonio Bonfatti headed the Mission in which other civil servants, private business owners, scientists, legislators and journalists participated.
     LIF’s Director Guillermo Cleti also attended BioAsia as one of the members of the Santa Fe Government’s Mission. He had a schedule of meetings with different Indian companies, mainly medicines and APIs manufacturers.

B2B meetings in New Delhi
     After BioAsia Forum, Guillermo Cleti participated in different meetings in New Delhi with other Indian manufacturers.
     These meetings took place in the Federation of Indian Chambers of Commerce and Industry (FICCI) headquarters and in the Sheraton Hotel on February 21st and 22nd.

LIF started medicine provision to the National Government

     LIF delivered 1.300.000 tablets of Metformin 500 mg (Antidiabetic); 3.400.000 tablets of Enalapril 10 mg (Antihypertensive) and 1.300.000 tablets of Simvastatin 20 mg (Hypolipidemic).
     That was the first provision of almost 30.000.000 tablets required by The National Health Ministry through REMEDIAR Program.
     Amoxicillin 500 mg, Cefalexin 500 mg, Paracetamol 500 mg y Glibenclamide 5 mg are other medicines that LIF is going to provide for the next six months.
     Glibenclamide is going to be produce by LIF together with Instituto Biológico de La Plata (another public laboratory of Buenos Aires province).

Simvastatin LIF
     Since 2002, REMEDIAR Program has delivered medicines in more than 7000 healthcare centers in Argentina.
     This year REMEDIAR Program added Simvastatin 20 mg to its vademecum.

International Women’s day at LIF

     LIF’s women staff members participated in the celebration of International Women’s day.
     The meeting took place at the LIF’s multiple purpose room where LIF’s Board of Directors gave flowers to all the women present.
     “I would like to recognize and to highlight the important role of women in society and mainly at LIF”, say LIF’s Director Diego Bruno.
     Finally, all the present shared a lunch.

LIF presented a project at the MINCyT to get a FONARSEC

     LIF presented a project at the MINCyT(1) to get a FONARSEC (2) for the research, development and production of medicines.

     FONARSEC is a financial instrument through which LIF might be able to get funds to improve its capacity of production.

     LIF and UNL(3) have signed a public consortium in which  both institutions will work in this project together.

     The main objective is firstly, to develop know how and finally, the production of medicines used in patients with tuberculosis.

     Thus, LIF will be able to produce four different medicines as:

- Rifampicin + Isoniazid + Pyrazinamide (triple association).
- Ethambutol.
- Rifampin + Isoniazid (double association).
- Isoniazid.

     LIF is going to build a new area for research and development where new equipment and machines will be incorporated.

     In this project, LIF is going to work during 36 months with other areas of the UNL like: Laboratorio de Control de Calidad de la Fac. de Bioquímica y Cs. Biológicas; Instituto de Tecnología Celulósica and Departamento de Ingeniería Industrial de la Facultad de Ingeniería Química. 

     Once this objective is reached, LIF will be able to provide these medicines to the National Government, who has had problems in buying them in the pharmaceutical market.

(1)MINCyT: Ministerio de Innovación, Ciencia y Tecnología.

(2)FONARSEC: Fondo Argentino Sectorial.

(3)UNL: Universidad Nacional del Litoral

Santa Fe’s Governor visited LIF

      Santa Fe’s Governor, Dr. Antonio Bonfatti, visited LIF where he had a meeting with the LIF’s Board of Directors.
     In this meeting, the LIF’s Board of Directors gave information about different activities such as: medicines production for Santa Fe province; the recent agreement with the National Health Ministry by which LIF will produce some medicines for REMEDIAR program; the news medicines developments and the project to build a new administrative area.
     “Today, there are 104 staff members, almost 40 employees more than 5 years ago. For that, we will need to build more offices”, said Guillermo Cleti (LIF’s Director).
     “Today, Santa Fe is a national example. Here, Public production of medicines is a true state policy.
     Since 2007, we have supported the growth of LIF with an important investment in building, training and technology”, said the Governor.
     Finally, the different production areas were shown by the LIF’s Board of Directors.
     Hugo Marcucci (Santa Fe Senator) and Miguel Gonzalez (Health Secretary) also participated in this visit.

LIF participated in The Second Lecture of Healthy Feeding

     The lecture took place on October 17th and 18th at the Metropolitano Convention Center in Rosario.
     More than 1000 people of different places of Argentina participated in the lectures and workshops.
     This meeting was organized by ASSAL* and LIF had its own institutional stand.

     LIF’s Director Guillermo Cleti and LIF’s staff members: Edgardo Ramírez and Melina Uriarte gave information about the Laboratory.

(*)ASSAL: Agencia Santafesina de Seguridad Alimentaria (Santa Fe’s Food Regulatory Agency)

LIF’s medicines are gluten free

     “The patients with celiac disease in Santa Fe can use medicines produced by LIF without any problem” said Ph. Guillermo Cleti (LIF’s Director).
     LIF and ASSAL(1) have recently signed an agreement in which ASSAL will do the tests for gluten at LIF’s medicines.
     Thus, LIF has sent to ASSAL the different APIs(2) and excipients utilized to produce medicines.
     The results were negative in all APIs and excipients. That is why, all LIF’s medicines are gluten free.
     “The next step will be to add the phrase “gluten free” at the packaging and prospects” confirmed Guillermo Cleti.
     In May 2013, ANMAT(3) published a new regulation for medicines gluten free which includes: definitions and a guideline for the use of the term “gluten free” at medicines

Celiac disease and gluten
     Gluten is a protein present in wheat, oats, barley and rye.

     Celiac disease is an autoimmune disorder in the small intestine. Patients with celiac disorder present gluten intolerance.
     Symptoms: pain and discomfort in the digestive tract, chronic constipation and diarrhea, failure to thrive (in children), anemia and fatigue.
(1)ASSAL: Agencia Santafesina de Seguridad Alimentaria (Santa Fe’s Food Regulatory Agency)
(2) Active Pharmaceutical Ingredient
(3) ANMAT: Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. (National Regulatory Agency for medicines, food and medical devices).